Latest news
Iconovo carries out a directed issue of shares of approx. SEK 25 million and a rights issue of shares of approx. SEK 24.6 million
The Board of Directors of Iconovo AB ("Iconovo" or the "Company") has today resolved on a directed share issue of approximately SEK 25 million (the…
Iconovo appoints Anders Månsson as new CEO
Iconovo AB (publ), a leader in the development of inhalable drugs based on proprietary inhalers and dry powder formulations, has today appointed Anders…
Press releases
Nov 30, 2023, 09:30
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Action
Other
Nov 30, 2023, 09:30
News
IR
English
Regulatory
Listing Regulation
Corporate Action
Other
Nov 29, 2023, 14:30
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
Nomination Committee
Nov 29, 2023, 14:30
News
IR
English
Regulatory
Listing Regulation
Corporate Information
Nomination Committee
Nov 16, 2023, 11:15
News
IR
English
Corporate Action
Other
Nov 16, 2023, 11:15
News
IR
Swedish
Corporate Action
Other
Oct 31, 2023, 08:30
News
IR
Swedish
Corporate Action
Other
mfn-cus-disclaimer
Oct 27, 2023, 14:00
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
General meeting
Raport bolagsstämman
Oct 27, 2023, 08:30
News
IR
Swedish
Regulatory
MAR
Report
Interim
Q3
Oct 17, 2023, 21:15
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Action
Other
mfn-cus-disclaimer
Sep 26, 2023, 23:35
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
General meeting
Notice
Sep 26, 2023, 23:30
News
IR
English
Regulatory
MAR
Corporate Action
Shares
Issuance
mfn-cus-top-disclaimer
Sep 26, 2023, 23:30
News
IR
Swedish
Regulatory
MAR
Corporate Action
Shares
Issuance
mfn-cus-top-disclaimer
Sep 26, 2023, 09:15
News
IR
Swedish
Corporate Action
Other
Sep 26, 2023, 09:15
News
IR
English
Corporate Action
Other
Sep 19, 2023, 08:30
News
IR
English
Corporate Action
Other
Sep 19, 2023, 08:30
News
IR
Swedish
Corporate Action
Other
Sep 13, 2023, 12:42
News
IR
Swedish
Corporate Action
Other
Sep 13, 2023, 12:42
News
IR
English
Corporate Action
Other
Possessing a unique combination
of engineering and pharma expertise, Iconovo can provide the optimal combination of customized inhalers and tailored formulations.
ICONOVO AB
VISITING ADDRESS
Ideon, Delta 6 Lund
Ideongatan 3B
POSTAL ADDRESS
Iconovo AB
Ideongatan 3A-B
SE-223 62 LUND
Sweden
CONTACT
Phone: +46 46 275 67 77
Director Business Development and Alliances
Måns Österberg
Mail: mans.osterberg@iconovo.se
Interim CEO
Anders Månsson
Mail: anders.mansson@iconovo.se